

BOARD OF GOVERNORS

Robert M. Barr, MD

President

Charlotte, North Carolina

Cheri L. Canon, MD

President-elect

Birmingham, Alabama

John A. Kaufman, MD Secretary-Treasurer Portland, Oregon

Kaled M. Alektiar, MD New York, New York

Donald J. Flemming, MD Hershey, Pennsylvania

Toby A. Gordon, ScDBaltimore, Maryland

Mary S. Newell, MD Atlanta, Georgia

Matthew B. Podgorsak, PhD
Buffalo, New York

EXECUTIVE LEADERSHIP

Brent Wagner, MD, MBA Executive Director Tucson, Arizona

ASSOCIATE EXECUTIVE DIRECTORS

N. Reed Dunnick, MD Diagnostic Radiology Ann Arbor, Michigan

James B. Spies, MD, MPH Interventional Radiology Washington, DC

Geoffrey S. Ibbott, PhD Medical Physics Jericho, Vermont

Paul E. Wallner, DO

Radiation Oncology

Moorestown, New Jersey

October 9, 2023

Coll

To Whom It May Concern:

Attached are the separate financial statements of The American Board of Radiology for the year ended December 31, 2022.

The accompanying statement of financial position as of December 31, 2022, and the related statement of activities for the year then ended have been prepared by Kelly M. Crandall, CPA. I have prepared such financial statements in my capacity as the Sr. Financial and Accounting Analyst of the organization.

Kelly M Crandall, CPA Sr. Financial and Accounting Analyst The American Board of Radiology



Statement of Financial Position

As of December 31, 2022

Total Liabilities and Net Assets	\$	42,904,628
Total Net Assets		39,185,314
YTD Increase (Decrease) in Net Assets		(5,647,186)
Unrestricted net assets, beginning of year		44,832,500
Total Liabilities		3,719,315
Deferred compensation liability		245,204
Deferred revenue		2,062,224
Accrued expenses		1,296,795
Accounts payable	\$	115,092
Total Assets	<u>\$</u>	42,904,628
Investments held for deferred compensation		245,204
Investments		33,675,288
Property, equipment and internally developed software, net		5,678,756
Prepaid expenses and other assets		617,570
Accounts receivable, net		506,972
Cash and cash equivalents	\$	2,180,838



Statement of Activities

For the Year Ended December 31, 2022

Application Fees		\$ 1,703,493
Annual Fees		10,800,352
Examination Fees		4,978,367
Cancellation and Penalty Fees		37,200
Other Revenue		42,860
	Total Revenues and Gains	17,562,272
Examination Expenses		233,903
Travel		1,028,050
Depreciation/Amortization Expense		877,535
Office Expenses		4,356,216
Personnel Expenses		11,505,869
Bad Debt Expense		355,463
Loss on Disposal of Property & Equip		22,527
	Total Expenses and Losses	18,379,564
	Net Operating Income (Loss)	(817,292)
Net Investment Income (Loss)		(5,680,493)
Miscellaneous Income		850,698
Income Tax Expense-UBTI		(100)
N	Non-Operating Revenue (Expense)	(4,829,895)
li	ncrease (Decrease) in Net Assets	\$ (5,647,186)